Home > Insider Trading > Filing (0001209191-22-030943)

Filing Details

Accession Number:: 0001209191-22-030943
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-05-20 15:29:06
Reporting Period:: 2022-05-19

Accepted Time:: 2022-05-20 15:29:06
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1117480	Chimerix Inc	CMRX	Pharmaceutical Preparations (2834)	330903395

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1267959	A Fred Middleton	C/O Chimerix, Inc. 2505 Meridian Parkway, Suite 100 Durham NC 27713		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-05-19	20,000	$2.04	20,000	No	4	P	Indirect	Fred A. Middleton Separate Property Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	Fred A. Middleton Separate Property Trust

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	207,523	Direct
Common Stock	2,776,093	Indirect	See footnote
Common Stock	531,861	Indirect	See footnote
Common Stock	3,446	Indirect	See footnote

Footnotes

The price reported in Column 4 is weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.02 to $2.05, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
The securities are held as follows: 829,046 shares of common stock held by Sanderling Venture Partners V, L.P., 233,134 shares of common stock held by Sanderling V Biomedical, L.P., 155,143 shares of common stock held by Sanderling V Limited Partnership, 138,046 shares of common stock held by Sanderling V Beteiligungs GmbH & Co. KG, 199,853 shares of common stock held by Sanderling V Biomedical Co-Investment Fund, L.P., 329,682 shares of common stock held by Sanderling Venture Partners V Co-Investment Fund, L.P. and 891,189 shares of common stock held by Sanderling V Strategic Exit Fund, L.P. (collectively, the Sanderling V Shares).
The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling V Shares and the Sanderling VI Shares (as defined herein). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
The securities are held as follows: 498,046 shares of common stock held by Sanderling Venture Partners VI Co-Investment Fund, L.P., 15,431 shares of common stock held by Sanderling VI Beteiligungs GmbH & Co. KG and 18,384 shares of common stock held by Sanderling VI Limited Partnership (collectively, the Sanderling VI Shares).
The securities are held by the Middleton-McNeil Retirement Trust, over which the reporting person shares voting and investment power. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.